Rigel Pharmaceuticals (NASDAQ:RIGL) was upgraded by analysts at
Wall Str
Rigel Pharmaceuticals (NASDAQ:RIGL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
How the Narrative Surrounding Rigel Pharmaceuticals Is Shifting After Upgraded Targets and Guidance [Yahoo! Finance]
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]